Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Abstract

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

What is claimed is:  
     
         1 . A method for the treatment of B cell lymphoma comprising the step of administering a therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody to a human.  
     
     
         2 . The method of  claim 1  wherein the amount of said antibody administered to said human is between about 0.001 to about 30 milligrams of antibody per kilogram body weight of said human (“mg/kg”).  
     
     
         3 . The method of  claim 1  wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as part of ATCC deposit number 69119.  
     
     
         4 . The method of  claim 1  further comprising the step of administering a second therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody.  
     
     
         5 . The method of  claim 4  wherein said additional administration of said antibody to said human occurs within about seven days of said first administration of said antibody to said human.  
     
     
         6 . A method for the treatment of B cell lymphoma comprising the steps of: 
 1) administering, at a first administration period, a first therapeutically effective amount of immunologically active, chimeric anti-CD20 antibody to a human;    2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody;    3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody.    
     
     
         7 . The method of  claim 6  wherein said first, second and third therapeutically effective amount of said antibody is between about 0.001 mg/kg to about 30 mg/kg.  
     
     
         8 . The method of  claim 6  wherein said second administration period is within about seven days of said first administration period.  
     
     
         9 . The method of  claim 6  wherein said third administration period is within about fourteen days of said first administration period.  
     
     
         10 . The method of  claim 6  wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).  
     
     
         11 . Immunologically active, chimeric anti-CD20 produced from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).  
     
     
         12 . A hybridoma which secretes anti-CD20 antibody, said hybridoma being identified by American Type Culture Collection deposit number HB 11388.  
     
     
         13 . A monoclonal antibody secreted from the hybridoma of  claim 12 .  
     
     
         14 . A radiolabeled antibody according to  claim 12 .  
     
     
         15 . The radiolabeled antibody of  claim 14  where the radiolabel is selected from the group consisting of yttrium [90]; indium [111], and iodine [131].  
     
     
         16 . A method for the treatment of B cell lymphoma comprising of steps of administering a therapeutically effective amount of the antibody of  claim 14  to a human.  
     
     
         17 . The method of  claim 16  when the radiolabel of said antibody is yttrium [90].  
     
     
         18 . A method for the treatment of B cell lymphoma comprising the steps of: 
 1) administering, at a first administration period, an immunology active chimeric anti-CD20 antibody to human; and    2) administering, at a second administration period, a radiolabeled anti-CD20 antibody to said human.    
     
     
         19 . The method of  claim 18  when said chimeric anti-CD20 is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as part of ATCC deposit number 69119.  
     
     
         20 . The method of  claim 8  when said radiolabeled antibody comprises a monoclonal antibody secreted from a hybridoma identified by American Type Culture Collection deposit number HB 11388.